{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:30:04Z","timestamp":1768408204250,"version":"3.49.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016190","name":"Trond Mohn Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005036","name":"University of Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Western Norway Regional Health Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clnu.2021.03.040","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T12:35:52Z","timestamp":1617453352000},"page":"2556-2575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5419-8927","authenticated-orcid":false,"given":"Elise","family":"Grytten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5866-5190","authenticated-orcid":false,"given":"Johnny","family":"Laupsa-Borge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-9273","authenticated-orcid":false,"given":"Pavol","family":"Bohov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bodil","family":"Bj\u00f8rndal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-8967","authenticated-orcid":false,"given":"Elin","family":"Strand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Skorve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Erik","family":"Nordrehaug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf K.","family":"Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen","family":"Rostrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-4986","authenticated-orcid":false,"given":"Gunnar","family":"Mellgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon N.","family":"Dankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ottar K.","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2021.03.040_bib1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.clnu.2021.03.040_bib2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"issue":"390","key":"10.1016\/j.clnu.2021.03.040_bib3","first-page":"1151","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study","volume":"2017","author":"Naghavi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2021.03.040_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.clnu.2021.03.040_bib5","article-title":"Hit or miss: the new cholesterol targets","author":"DuBroff","year":"2020","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.00033.2011","article-title":"Pathophysiology of human visceral obesity: an update","volume":"93","author":"Tchernof","year":"2013","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clnu.2021.03.040_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrcardio.2010.223","article-title":"Lipid parameters for measuring risk of cardiovascular disease","volume":"8","author":"Arsenault","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clnu.2021.03.040_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib10","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib11","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacl.2020.04.009","article-title":"The association between triglycerides and incident cardiovascular disease: what is \u201coptimal\u201d?","volume":"14","author":"Aberra","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib12","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","article-title":"LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management","volume":"1","author":"Cromwell","year":"2007","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib14","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1161\/ATVBAHA.109.190405","article-title":"Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk","volume":"29","author":"Musunuru","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clnu.2021.03.040_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MOL.0b013e32833b7756","article-title":"Lipoprotein subfractions and cardiovascular disease risk","volume":"21","author":"Krauss","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib16","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/CIRCULATIONAHA.118.035432","article-title":"Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence","volume":"138","author":"Aday","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.95.1.69","article-title":"Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Qu\u00e9bec Cardiovascular Study","volume":"95","author":"Lamarche","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2017.07.003","article-title":"LDL subfractions are associated with incident cardiovascular disease in the Malm\u00f6 Prevention Project Study","volume":"263","author":"Shiffman","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2021.03.040_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-150-2-200901200-00006","article-title":"High-density lipoprotein particle size and concentration and coronary risk","volume":"150","author":"El Harchaoui","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.120.045713","article-title":"Associations between HDL particles and ischemic events by vascular domain, gender, and ethnicity: a pooled cohort analysis","volume":"142","author":"Singh","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib22","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2021.03.040_bib24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population","volume":"30","author":"Sierra-Johnson","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clnu.2021.03.040_bib25","doi-asserted-by":"crossref","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clnu.2021.03.040_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11883-003-0036-8","article-title":"The concept of apolipoprotein-defined lipoprotein families and its clinical significance","volume":"5","author":"Alaupovic","year":"2003","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.clnu.2021.03.040_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis","volume":"9","author":"Wyler von Ballmoos","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib29","doi-asserted-by":"crossref","first-page":"1645S","DOI":"10.1093\/ajcn\/65.5.1645S","article-title":"n-3 fatty acids and serum lipoproteins: human studies","volume":"65","author":"Harris","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib30","doi-asserted-by":"crossref","first-page":"1628S","DOI":"10.1093\/ajcn\/65.5.1628S","article-title":"Individual fatty acid effects on plasma lipids and lipoproteins: human studies","volume":"65","author":"Kris-Etherton","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib31","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib32","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1567-5688(13)70005-9","article-title":"Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, double blind, placebo controlled trials","volume":"14","author":"Casula","year":"2013","journal-title":"Atherosclerosis Suppl"},{"key":"10.1016\/j.clnu.2021.03.040_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Reduce-It Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib35","doi-asserted-by":"crossref","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials Involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clnu.2021.03.040_bib36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/CIRCULATIONAHA.114.010236","article-title":"Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies","volume":"130","author":"Farvid","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"American Heart Association. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib38","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1161\/CIRCULATIONAHA.118.038908","article-title":"Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality: an individual-level pooled analysis of 30 cohort studies","volume":"139","author":"Marklund","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib39","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55\u2008000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2021.03.040_bib40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/77.2.300","article-title":"Randomized controlled trial of the effect of n\u20133 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity","volume":"77","author":"Chan","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3945\/ajcn.110.003871","article-title":"Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia","volume":"93","author":"Skulas-Ray","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.clnu.2021.03.040_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12944-015-0049-7","article-title":"A\u00a0review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals","volume":"14","author":"Leslie","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib44","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/advances\/nmy038","article-title":"\u03c9-6 polyunsaturated fatty acids and cardiometabolic health: current evidence, controversies, and research gaps","volume":"9","author":"Maki","year":"2018","journal-title":"Adv Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Omega-3 Treatment Trialists C. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77\u00a0917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib46","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.clnu.2021.03.040_bib47","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1001\/jama.2020.22387","article-title":"Effects of omega-3 fatty acids on major adverse cardiovascular events: what matters most: the drug, the dose, or the placebo?","volume":"324","author":"Sharma","year":"2020","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.clnu.2021.03.040_bib48","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1017\/S0007114510004010","article-title":"n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials","volume":"104","author":"Ramsden","year":"2010","journal-title":"Br J Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12937-017-0254-5","article-title":"The effect of replacing saturated fat with mostly n-6 polyunsaturated fat on coronary heart disease: a meta-analysis of randomised controlled trials","volume":"16","author":"Hamley","year":"2017","journal-title":"Nutr J"},{"key":"10.1016\/j.clnu.2021.03.040_bib50","article-title":"Omega-6 fats for the primary and secondary prevention of cardiovascular disease","volume":"11","author":"Hooper","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clnu.2021.03.040_bib51","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"3","author":"Abdelhamid","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clnu.2021.03.040_bib52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-nutr-071816-064614","article-title":"Dietary fat and risk of cardiovascular disease: recent controversies and advances","volume":"37","author":"Wang","year":"2017","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.amjcard.2005.12.026","article-title":"Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids","volume":"98","author":"Robinson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2007.11.008","article-title":"Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives","volume":"197","author":"Harris","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2021.03.040_bib56","doi-asserted-by":"crossref","first-page":"1981S","DOI":"10.1093\/ajcn\/87.6.1981S","article-title":"Role of n\u22123 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease","volume":"87","author":"Jacobson","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1753-4887.2010.00272.x","article-title":"Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides","volume":"68","author":"Musa-Veloso","year":"2010","journal-title":"Nutr Rev"},{"key":"10.1016\/j.clnu.2021.03.040_bib58","first-page":"843","article-title":"Fish oil: how does it reduce plasma triglycerides?","volume":"2012","author":"Shearer","year":"1821","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clnu.2021.03.040_bib59","series-title":"Omega-3 fatty acids and cardiovascular disease: an updated systematic review. Evidence report\/technology assessment No. 223. (Prepared by the Brown evidence-based practice center under contract No. 290-2012-00012-I.) AHRQ publication No. 16-E002-EF","author":"Balk","year":"2016"},{"key":"10.1016\/j.clnu.2021.03.040_bib60","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/01.ATV.13.10.1533","article-title":"Effects of canola, corn, and olive oils on fasting and postprandial plasma lipoproteins in humans as part of a National Cholesterol Education Program Step 2 diet","volume":"13","author":"Lichtenstein","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.clnu.2021.03.040_bib61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/nure.12033","article-title":"Evidence of health benefits of canola oil","volume":"71","author":"Lin","year":"2013","journal-title":"Nutr Rev"},{"key":"10.1016\/j.clnu.2021.03.040_bib62","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1194\/jlr.P085522","article-title":"Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis","volume":"59","author":"Schwingshackl","year":"2018","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib63","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ajcn\/86.2.324","article-title":"Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men","volume":"86","author":"Kelley","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib64","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.ejcn.1602703","article-title":"Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes","volume":"62","author":"Mostad","year":"2008","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/FJC.0b013e318210fca5","article-title":"Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia","volume":"57","author":"Maki","year":"2011","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.clnu.2021.03.040_bib67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jacl.2011.09.001","article-title":"Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia","volume":"5","author":"Maki","year":"2011","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib68","first-page":"207","article-title":"Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults","volume":"141","author":"Neff","year":"2011","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib69","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacl.2012.07.001","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study)","volume":"6","author":"Bays","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib70","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.numecd.2010.12.010","article-title":"Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects","volume":"22","author":"Bragt","year":"2012","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12944-015-0100-8","article-title":"Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial","volume":"14","author":"Dunbar","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib72","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1017\/S0007114517001167","article-title":"High-quality fish oil has a more favourable effect than oxidised fish oil on intermediate-density lipoprotein and LDL subclasses: a randomised controlled trial","volume":"117","author":"Rundblad","year":"2017","journal-title":"Br J Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib73","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/bmj.311.7017.1401","article-title":"Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample","volume":"311","author":"Han","year":"1995","journal-title":"BMJ"},{"issue":"i\u2013xii","key":"10.1016\/j.clnu.2021.03.040_bib74","first-page":"1","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","author":"World Health Organization","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.clnu.2021.03.040_bib75","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib76","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jacl.2014.12.001","article-title":"Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia","volume":"9","author":"Skulas-Ray","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.clnu.2021.03.040_bib77","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF02529870","article-title":"n-3 fatty acids and lipoproteins: comparison of results from human and animal studies","volume":"31","author":"Harris","year":"1996","journal-title":"Lipids"},{"key":"10.1016\/j.clnu.2021.03.040_bib78","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/jmf.2008.1250","article-title":"Dose-response of n-3 polyunsaturated fatty acids on lipid profile and tolerability in mildly hypertriglyceridemic subjects","volume":"12","author":"Park","year":"2009","journal-title":"J\u00a0Med Food"},{"key":"10.1016\/j.clnu.2021.03.040_bib79","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.2903\/j.efsa.2010.1796","volume":"8","author":"EFSA Panel on Dietetic Products NaA","year":"2010","journal-title":"EFSA J"},{"key":"10.1016\/j.clnu.2021.03.040_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2013.03.010","article-title":"Bioavailability of long-chain omega-3 fatty acids","volume":"89","author":"Schuchardt","year":"2013","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"10.1016\/j.clnu.2021.03.040_bib81","doi-asserted-by":"crossref","first-page":"g2272","DOI":"10.1136\/bmj.g2272","article-title":"Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys","volume":"348","author":"Micha","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2021.03.040_bib82","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCULATIONAHA.108.191627","volume":"119","author":"Harris","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jada.2009.12.006","article-title":"The debate about n-6 polyunsaturated fatty acid recommendations for cardiovascular health","volume":"110","author":"Kris-Etherton","year":"2010","journal-title":"J\u00a0Am Diet Assoc"},{"key":"10.1016\/j.clnu.2021.03.040_bib84","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1476-511X-11-82","article-title":"Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat","volume":"11","author":"Strand","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.plipres.2008.03.003","article-title":"Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake","volume":"47","author":"Hodson","year":"2008","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib86","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12944-017-0515-5","article-title":"Effects of aerobic exercise on lipids and lipoproteins","volume":"16","author":"Wang","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib87","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10840-009-9466-8","article-title":"Fatty acid percentage in erythrocyte membranes of atrial flutter\/fibrillation patients and controls","volume":"27","author":"Viviani Anselmi","year":"2010","journal-title":"J\u00a0Intervent Card Electrophysiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib88","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11745-012-3665-2","article-title":"Statistical methodological issues in handling of fatty acid data: percentage or concentration, imputation and indices","volume":"47","author":"Mocking","year":"2012","journal-title":"Lipids"},{"key":"10.1016\/j.clnu.2021.03.040_bib89","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00394-016-1358-y","article-title":"Absolute versus relative measures of plasma fatty acids and health outcomes: example of phospholipid omega-3 and omega-6 fatty acids and all-cause mortality in women","volume":"57","author":"Miura","year":"2018","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0002-9149(02)02632-2","article-title":"Measurement issues related to lipoprotein heterogeneity","volume":"90","author":"Otvos","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib91","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cll.2006.07.006","article-title":"Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy","volume":"26","author":"Jeyarajah","year":"2006","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib92","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2021.03.040_bib93","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/met.2014.0050","article-title":"Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance","volume":"12","author":"Shalaurova","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.clnu.2021.03.040_bib94","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/45.4.561","article-title":"Within- and between-subject variation in commonly measured anthropometric and biochemical variables","volume":"45","author":"Widjaja","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.clnu.2021.03.040_bib95","doi-asserted-by":"crossref","first-page":"e21403","DOI":"10.1371\/journal.pone.0021403","article-title":"Problems with using the normal distribution \u2013 and ways to improve quality and efficiency of data analysis","volume":"6","author":"Limpert","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.clnu.2021.03.040_bib96","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/sim.5713","article-title":"Seven myths of randomisation in clinical trials","volume":"32","author":"Senn","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib97","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1002\/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F","article-title":"Sympercents: symmetric percentage differences on the 100 loge scale simplify the presentation of log transformed data","volume":"19","author":"Cole","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib98","doi-asserted-by":"crossref","first-page":"1914S","DOI":"10.3945\/ajcn.110.000893","article-title":"Sex-specific differences in essential fatty acid metabolism","volume":"94","author":"Decsi","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1476-511X-11-42","article-title":"Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials","volume":"11","author":"Wang","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2014when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib101","doi-asserted-by":"crossref","first-page":"l4378","DOI":"10.1136\/bmj.l4378","article-title":"CONSORT 2010 statement: extension to randomised crossover trials","volume":"366","author":"Dwan","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2021.03.040_bib102","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.clnu.2021.03.040_bib103","doi-asserted-by":"crossref","first-page":"1997S","DOI":"10.1093\/ajcn\/87.6.1997S","article-title":"The omega-3 index as a risk factor for coronary heart disease","volume":"87","author":"Harris","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib104","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ajcn\/66.3.649","article-title":"Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids","volume":"66","author":"Grimsgaard","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ajcn\/84.3.540","article-title":"Effects of n\u22123 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation","volume":"84","author":"Mostad","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib106","first-page":"10","article-title":"Omega-3 fatty acid supplementation for 12 weeks increases resting and exercise metabolic rate in healthy community-dwelling older females","author":"Logan","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.clnu.2021.03.040_bib107","first-page":"12","article-title":"Lack of effects of fish oil supplementation for 12 weeks on resting metabolic rate and substrate oxidation in healthy young men: a randomized controlled trial","author":"Jannas-Vela","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.clnu.2021.03.040_bib108","first-page":"8","article-title":"Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism","author":"Green","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.clnu.2021.03.040_bib109","doi-asserted-by":"crossref","first-page":"101008","DOI":"10.1016\/j.plipres.2019.101008","article-title":"Updates to the n-3 polyunsaturated fatty acid biosynthesis pathway: DHA synthesis rates, tetracosahexaenoic acid and (minimal) retroconversion","volume":"76","author":"Metherel","year":"2019","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib110","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1016\/j.bmc.2018.07.004","article-title":"Construction of a series of intermediates in the \u03b2-oxidation pathway from THA to EPA via DHA in free acid form","volume":"26","author":"Kanamori","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.clnu.2021.03.040_bib111","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/ajcn\/nqz097","article-title":"Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial","volume":"110","author":"Metherel","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib112","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ajcn\/58.4.497","article-title":"Simple relationships exist between dietary linoleate and the n\u22126 fatty acids of human neutrophils and plasma","volume":"58","author":"James","year":"1993","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib113","first-page":"945","article-title":"Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men","volume":"137","author":"Liou","year":"2007","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-7075-8-36","article-title":"Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review","volume":"8","author":"Rett","year":"2011","journal-title":"Nutr Metab"},{"key":"10.1016\/j.clnu.2021.03.040_bib115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1365-2362.1999.00477.x","article-title":"Comparison of bolus versus fractionated oral applications of [13C]-linoleic acid in humans","volume":"29","author":"Demmelmair","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.clnu.2021.03.040_bib116","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ajcn\/82.3.510","article-title":"Small differences in the effects of stearic acid, oleic acid, and linoleic acid on the serum lipoprotein profile of humans","volume":"82","author":"Thijssen","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib117","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.amjcard.2008.03.078","article-title":"Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg\/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia","volume":"102","author":"Maki","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clnu.2021.03.040_bib118","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1194\/jlr.M200282-JLR200","article-title":"Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance","volume":"44","author":"Park","year":"2003","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib119","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.plipres.2016.05.001","article-title":"Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults","volume":"63","author":"Stark","year":"2016","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib120","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1194\/jlr.M600200-JLR200","article-title":"Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans","volume":"47","author":"Vedala","year":"2006","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib121","doi-asserted-by":"crossref","first-page":"R199","DOI":"10.1530\/JME-13-0277","article-title":"Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease","volume":"52","author":"Nielsen","year":"2014","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.clnu.2021.03.040_bib122","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0022-2275(20)30473-9","article-title":"Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype","volume":"43","author":"Khan","year":"2002","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib123","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S0007114598001585","article-title":"Lipoprotein lipase and the disposition of dietary fatty acids","volume":"80","author":"Fielding","year":"1998","journal-title":"Br J Nutr"},{"issue":"36 Suppl","key":"10.1016\/j.clnu.2021.03.040_bib124","first-page":"S91","article-title":"The effect of n\u22123 fatty acids on low density lipoprotein subfractions","author":"Griffin","year":"2001","journal-title":"Lipids"},{"key":"10.1016\/j.clnu.2021.03.040_bib125","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1194\/jlr.R200004-JLR200","article-title":"Metabolic origins and clinical significance of LDL heterogeneity","volume":"43","author":"Berneis","year":"2002","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib126","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1161\/01.ATV.17.12.3542","article-title":"Lipoprotein heterogeneity and apolipoprotein B metabolism","volume":"17","author":"Packard","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clnu.2021.03.040_bib127","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1161\/ATVBAHA.114.303458","article-title":"All low-density lipoprotein particles are not created equal","volume":"34","author":"Krauss","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clnu.2021.03.040_bib128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0021-9150(90)90045-K","article-title":"Changes in lipoprotein composition in hypertriglyceridemic patients taking cholesterol-free fish oil supplements","volume":"82","author":"Inagaki","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2021.03.040_bib129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clnu.2021.03.040_bib130","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/nu9101099","article-title":"The role of omega-3 fatty acids in reverse cholesterol transport: a review","volume":"9","author":"Pizzini","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2021.03.040_bib131","first-page":"256","article-title":"Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia","volume":"62","author":"Nozaki","year":"1992","journal-title":"Int J Vitam Nutr Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib132","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11745-001-0735-3","article-title":"Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells","volume":"36","author":"Hirano","year":"2001","journal-title":"Lipids"},{"key":"10.1016\/j.clnu.2021.03.040_bib133","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport","volume":"96","author":"Lewis","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib134","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clnu.2021.03.040_bib135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0021-9150(03)00006-6","article-title":"High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions","volume":"168","author":"Barter","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2021.03.040_bib136","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.atherosclerosis.2015.05.013","article-title":"Metabolism of apolipoprotein A-II containing triglyceride rich ApoB lipoproteins in humans","volume":"241","author":"Desai","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clnu.2021.03.040_bib137","doi-asserted-by":"crossref","first-page":"e100376","DOI":"10.1371\/journal.pone.0100376","article-title":"Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation","volume":"9","author":"van Schalkwijk","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.clnu.2021.03.040_bib138","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ajcn\/nqx013","article-title":"Substitution of dietary \u03c9-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial","volume":"107","author":"Drouin-Chartier","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib139","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1194\/jlr.M008961","article-title":"Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy","volume":"51","author":"Nicholls","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12944-016-0258-8","article-title":"The relationship between Lp(a) and CVD outcomes: a systematic review","volume":"15","author":"Forbes","year":"2016","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clnu.2021.03.040_bib141","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3402\/fnr.v55i0.5792","article-title":"Determination of lipid oxidation products in vegetable oils and marine omega-3 supplements","volume":"55","author":"Halvorsen","year":"2011","journal-title":"Food Nutr Res"},{"key":"10.1016\/j.clnu.2021.03.040_bib142","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lwt.2018.11.044","article-title":"Oxidation products from omega-3 and omega-6 fatty acids during a simulated shelf life of edible oils","volume":"101","author":"Nogueira","year":"2019","journal-title":"LWT - Food Sci Technol (Lebensmittel-Wissenschaft -Technol)"},{"key":"10.1016\/j.clnu.2021.03.040_bib143","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3736\/jintegrmed2013002","article-title":"Differential effects of adulterated versus unadulterated forms of linoleic acid on cardiovascular health","volume":"11","author":"Anton","year":"2013","journal-title":"J\u00a0Integr Med"},{"key":"10.1016\/j.clnu.2021.03.040_bib144","doi-asserted-by":"crossref","first-page":"e8707","DOI":"10.1136\/bmj.e8707","article-title":"Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis","volume":"346","author":"Ramsden","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2021.03.040_bib145","doi-asserted-by":"crossref","first-page":"i1246","DOI":"10.1136\/bmj.i1246","article-title":"Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73)","volume":"353","author":"Ramsden","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.clnu.2021.03.040_bib146","first-page":"5","article-title":"Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis","author":"DiNicolantonio","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.clnu.2021.03.040_bib147","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1079\/PHN2002404","article-title":"Variability of fish consumption within the 10 European countries participating in the European Investigation into Cancer and Nutrition (EPIC) study","volume":"5","author":"Welch","year":"2002","journal-title":"Publ Health Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib148","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0197-2456(86)90036-X","article-title":"Using baseline measurements in the two-period crossover clinical trial","volume":"7","author":"Willian","year":"1986","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.clnu.2021.03.040_bib149","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0197-2456(89)90065-2","article-title":"A\u00a0critique of recent research on the two-treatment crossover design","volume":"10","author":"Fleiss","year":"1989","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.clnu.2021.03.040_bib150","first-page":"10","article-title":"Design, analysis, and reporting of crossover trials for inclusion in a meta-analysis","author":"Li","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.clnu.2021.03.040_bib151","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ejcn.2015.213","article-title":"Effects of dietary saturated and n-6 polyunsaturated fatty acids on the incorporation of long-chain n-3 polyunsaturated fatty acids into blood lipids","volume":"70","author":"Dias","year":"2016","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnu.2021.03.040_bib152","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.clinthera.2013.07.420","article-title":"A\u00a0highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)","volume":"35","author":"Maki","year":"2013","journal-title":"Clin Therapeut"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561421001874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561421001874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T01:01:30Z","timestamp":1759366890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561421001874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":152,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0261561421001874"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2021.03.040","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in lipoprotein particle subclasses, standard lipids, and apolipoproteins after supplementation with n-3 or n-6 PUFAs in abdominal obesity: A randomized double-blind crossover study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2021.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}